Registry for Longitudinal Mortality and Therapy in Patients With Heart Failure (GREARTWAL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04062500 |
Recruitment Status :
Recruiting
First Posted : August 20, 2019
Last Update Posted : August 20, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Heart Failure | Other: Mortality and Rehospitalization rate |
Registry for Longitudinal mortality and therapy in patients with Heart Failure is a large, multicenter, prospective, open-label registry of the management of patients treated in the hospital for acute heart failure in China. The objective of this study is to investigate the clinical features and prognosis of patients with heart failure, and discover the characteristics of high-risk heart failure patients, and elucidate critical factors which predict the development and outcomes of symptomatic heart failure patients.
- To elucidate the clinical characteristics and prognostic risks of patients with heart failure.
- To study the characteristics of high-risk heart failure patients and predict the key factors for the development of symptomatic heart failure patients.
- To elucidate the compliance of patients with heart failure and the incidence of adverse drug effects.
- To investigate the effect of self-management on outcomes in patients with heart failure.
- To elucidate critical factors associated with the development and outcomes of heart failure.
- To investigate hospitalization expenses for heart failure.
Study Type : | Observational |
Estimated Enrollment : | 10500 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Registry for Longitudinal Mortality and Therapy in Patients With Heart Failure (GREARTWAL Study) |
Actual Study Start Date : | January 1, 2018 |
Estimated Primary Completion Date : | December 31, 2019 |
Estimated Study Completion Date : | December 31, 2027 |

Group/Cohort | Intervention/treatment |
---|---|
Patients with heart failure
patients treated in the hospital for acute heart failure in China
|
Other: Mortality and Rehospitalization rate
Mortality and Re-hospitalization of acute decompensated heart failure |
- Mortality of acute decompensated heart failure [ Time Frame: 10 years ]In-hospital and Annual mortality
- Re-hospitalization rate [ Time Frame: 10 years ]Re-hospitalization of acute decompensated heart failure
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- 1. 18 years and older. 2. Meet the diagnostic criteria of China 2018 or JACC/AHA 2017 or ESC 2016 heart failure guidelines.
3. Agree to be tested and sign an informed consent certificate.
Exclusion Criteria:
- 1. Age<18 years old. 2. Patients who refused to participate. 3. Patients may have a life expectancy of less than 1 years due to non- heart failure clinical conditions.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04062500
Contact: Dachun Xu, PhD | 18917684045 ext +86 | xdc77@tongji.edu.cn |
China, Shanghai | |
Shanghai Tenth People's Hospital, Tongji University | Recruiting |
Shanghai, Shanghai, China, 200072 | |
Contact: Dachun Xu, MD,PhD +86 18917684045 xdc77@tongji.edu.cn | |
Contact: Yawei Xu, MD,PhD +86 13916698181 xuyawei@tongji.edu.cn |
Principal Investigator: | Dachun Xu, PhD | Shanghai Tenthth People's Hospital |
Responsible Party: | Ya-Wei Xu, MD, pHD, Director of Cardiovascular Department, Shanghai 10th People's Hospital |
ClinicalTrials.gov Identifier: | NCT04062500 History of Changes |
Other Study ID Numbers: |
GREARTWAL |
First Posted: | August 20, 2019 Key Record Dates |
Last Update Posted: | August 20, 2019 |
Last Verified: | August 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Heart Failure,prognostic, registry |
Heart Failure Heart Diseases Cardiovascular Diseases |